Literature DB >> 20854046

Significant bronchodilator responsiveness and "reversibility" in a population sample.

Heather A Prentice1, David M Mannino, Glyn G Caldwell, Heather M Bush.   

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is defined by being "not fully reversible", most guidelines recommend measurement of lung function after the administration of a bronchodilator. The objective of this study was to compare bronchodilator responsiveness (significant improvement in the FEV(1) or FVC) to full-, partial- or "inverse'" reversibility in obstruction status in a population-based sample in Southeastern Kentucky. The study population was selected using random digit dialing of an adult population in Southeastern Kentucky as part of the Burden of Lung disease (BOLD) project. Lung function was assessed using spirometry pre- and post-bronchodilation. Subjects presence and severity of COPD was classified using modified Global Obstructive Lung Disease (GOLD) criteria. We examined the relation between changes in "obstruction" status (based on the FEV(1)/ FVC of 0.7) and the presence of "significant bronchodilator responsiveness" (based on ≥ 12% improvement in the FEV(1) or the FVC). The final population with acceptable pre- and post-bronchodilator spirometry included 440 participants. 32/440 subjects (7.3%) changed from obstructed to unobstructed (full-reversibility), 19/440 (4.3%) changed from unobstructed to obstructed ("inverse"-reversibility), 389/440 (88.4%) had either no-change or partial-reversibility, and 65/440 (14.8%) had bronchodilator responsiveness. Among those with full-reversibility, only 9/32 (28.1%) had bronchodilator responsiveness, whereas among subjects with "inverse"-reversibility, 10/19 (52.6%) had bronchodilator responsiveness. Among all subjects with bronchodilator responsiveness, only 19/65 (29.2%) changed categories. Our findings suggest that significant bronchodilator responsiveness is not the same as "reversibility" of "obstruction", even though these terms are often used interchangeably.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20854046     DOI: 10.3109/15412555.2010.510161

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  4 in total

1.  Small airway dysfunction and flow and volume bronchodilator responsiveness in patients with chronic obstructive pulmonary disease.

Authors:  Roberta Pisi; Marina Aiello; Andrea Zanini; Panagiota Tzani; Davide Paleari; Emilio Marangio; Antonio Spanevello; Gabriele Nicolini; Alfredo Chetta
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-06-19

2.  Bronchodilator responsiveness or reversibility in asthma and COPD - a need for clarity.

Authors:  Igor Barjaktarevic; Robert Kaner; Russell G Buhr; Christopher B Cooper
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-10-23

3.  The Effectiveness and Harms of Screening for Chronic Obstructive Pulmonary Disease: An Updated Systematic Review and Meta-Analysis.

Authors:  Chin Kook Rhee; Younhee Kim; Nahye Choi; Suhyun Jang; Kwang Ha Yoo
Journal:  J Korean Med Sci       Date:  2022-04-11       Impact factor: 2.153

4.  Computed tomography structural lung changes in discordant airflow limitation.

Authors:  Firdaus A A Mohamed Hoesein; Pim A de Jong; Jan-Willem J Lammers; Willem Pthm Mali; Michael Schmidt; Harry J de Koning; Carlijn van der Aalst; Matthijs Oudkerk; Rozemarijn Vliegenthart; Bram van Ginneken; Eva M van Rikxoort; Pieter Zanen
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.